The TGF-β Antibody #3711 detects recombinant TGF-β1, TGF-β2, and TGF-β3. The antibody also detects endogenous levels of the TGF-β1 precursor proteins. The different sizes we have listed represent the precursor TGF-β protein (45kDa), the mature dimer form (25kDa) and the monomer (12kDa).We do not usually detect the mature TGF-β at 25 kDa because mature TGF-β is composed of two polypeptides that are disulfide-linked. Therefore under reducing conditions, these polypeptides are separated and observed as a single band at 12 kDa. However, we have shown that the TGF-β Antibody #3711 can detect the mature form of TGF-β by using recombinant protein.TGF-β is rapidly exported from the cell and therefore may be difficult to detect in tissue or cell lysates. In human platelet samples, we observe two strong bands, with the larger band likely being the precursor (uncleaved) form at 45kDa and the smaller being the monomer at 12kDa.
An antibody shouldn’t be one of the variables in your experiment. Find out why customers rank CST highest for antibody specificity and sensitivity.
Ensure equal sample loading with loading control antibodies from CST.
Discover the PI3K Akt pathway and its crucial role in cell growth and survival. Click here to learn more & gain insights into this important signaling cascade
A scientific resource for the 14-3-3 protein domain containing information on structure, function, and binding to phospho-serine and phospho-threonine motifs.
Learn about BCR signaling and how it can lead to changes in cell metabolism, gene expression, and cytoskeletal organization. Click here.
U.S. Patent No. 6,441,140, directed to the production of a novel class of motif-specific, context-independent antibodies, highly useful for the identification of subclasses of protein kinase substrates.
Expert-reviewed interactive dopamine signaling pathway providing a current overview of Dopamine in Parkinson's Disease. Learn more here.
Feb 2008, CST continued collaboration with AstraZeneca to provide CST’s PhosphoScan® Platform for kinase inhibitor proteomic profiling.
Highly specific and sensitive rabbit mAbs against B7 family targets, B7-H3 & B7-H4, are proven to outperform existing clones by WB.
Get information on ordering or contacting Cell Signaling Technology. CST is happy to answer your questions. Select the team you need to contact.
CST and The Michael J. Fox Foundation (MJFF) announce a partnership to develop high-quality monoclonal antibodies against promising Parkinson’s disease (PD) targets.
Designing or troubleshooting flow cytometry experiments to analyze intracellular signaling? Here’s what you need to know.
MEDx and CST announce expansion of their ongoing partnership for companion diagnostic (CDx) development using CST® antibodies to meet growing demand in China.
Dec 2011, CST wins "Best Performing Antibodies" and "Best Breakthrough Products Cancer Research" Categories in Life Science Industry Awards.
Cell Signaling Technology, a leading provider of antibodies, kits and services, announced today that it has won two Life Science Industry Awards® for "Best Antibodies" and "Most Useful Website."
CiteAb Names Cell Signaling Technology, "Antibody Company of the Year" and "Researchers’ Choice"
Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, was honored with the 2017 CiteAb Award for &quoPTM Antibody Company of the Year" and for a third year in a row with the award for "Researchers’ Choice."
Tissue clearing has paved the way for intact brain imaging with molecular phenotyping. The technology is rapidly evolving and shows great potential.